Regulus Therapeutics Shares Up 42% On Heavy Volume (~196K Shares) Following Co. Press Release Previewing Will Present Preclinical Data On RGLS4326 In Development For Autosomal Dominant Polycystic Kidney Disease At American Society of Nephrology Oct. 25
Benzinga Newsdesk